The relevance of EGFR overexpression for the prediction of the malignant transformation of oral leukoplakia

Oncology Reports

Volumn 30, Issue 3, 2013, Pages 1149-1156

  Ries, Jutta ^a   Vairaktaris, Eleftherios ^b   Agaimy, Abbas ^a   Bechtold, Moritz ^a   Gorecki, Patricia ^a   Neukam, Friedrich W ^a   Nkenke, Emeka ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

EGFR overexpression; Immunohistochemistry; Malignant transformation; Oral leukoplakia; Oral squamous cell carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; ARTICLE; CANCER GRADING; CANCER GROWTH; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EGFR GENE; EPITHELIUM DYSPLASIA; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MOUTH SQUAMOUS CELL CARCINOMA; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TUMOR DIFFERENTIATION;

CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPLASIA; IMMUNOENZYME TECHNIQUES; LEUKOPLAKIA, ORAL; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; NEOPLASM GRADING; PRECANCEROUS CONDITIONS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84880605357     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2545     Document Type: Article

References (38)

1. Gondos A, Arndt V, Holleczek B, Stegmaier C, Ziegler H and Brenner H: Cancer survival in Germany and the United States at the beginning of the 21st century: an up-to-date comparison by period analysis. Int J Cancer 121: 395-400, 2007.
2. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
3. Lung T, Tascau OC, Almasan HA and Muresan O: Head and neck cancer, treatment, evolution and post therapeutic survival. Part 2: a decade's results 1993-2002. J Craniomaxillofac Surg 35: 126-131, 2007.
4. Warnakulasuriya S, Johnson NW and van der Waal I: Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 36: 575-580, 2007.
5. van der Waal I: Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol 45: 317-323, 2009.
6. Reibel J: Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med 14: 47-62, 2003.
7. Pitiyage G, Tilakaratne WM, Tavassoli M and Warnakulasuriya S: Molecular markers in oral epithelial dysplasia: review. J Oral Pathol Med 38: 737-752, 2009.
8. Pindborg JJ, Reichart P, Smith CJ and Waal I: World Health Organization: histological typing of cancer and precancer of the oral mucosa. Springer-Verlag, Berlin, pp47-62, 1997.
9. Warnakulasuriya S, Reibel J, Bouquot J and Dabelsteen E: Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med 37: 127-133, 2008.
10. Fleskens S and Slootweg P: Grading systems in head and neck dysplasia: their prognostic value, weaknesses and utility. Head Neck Oncol 1: 11, 2009.
11. Warnakulasuriya S: Lack of molecular markers to predict malignant potential of oral precancer. J Pathol 190: 407-409, 2000.
12. Ha PK, Chang SS, Glazer CA, Califano JA and Sidransky D: Molecular techniques and genetic alterations in head and neck cancer. Oral Oncol 45: 335-339, 2009.
13. Nasser W, Flechtenmacher C, Holzinger D, Hofele C and Bosch FX: Aberrant expression of p53, p16INK4a and Ki-67 as basic biomarker for malignant progression of oral leukoplakias. J Oral Pathol Med 40: 629-635, 2011.
14. Ries J, Agaimy A, Vairaktaris E, Gorecki P, Neukam FW, Strassburg LH and Nkenke E: Detection of MAGE-A expression predicts malignant transformation of oral leukoplakia. Cancer Invest 30: 495-502, 2012.
15. Ries J, Agaimy A, Vairaktaris E, Kwon Y, Strassburg LH, Neukam FW and Nkenke E: Evaluation of MAGE-A expression and grade of dysplasia for predicting malignant progression of oral leukoplakia. Int J Oncol 41: 1085-1093, 2012.
16. Ries J, Ponader S, Mollaoglu N, Vairaktaris E, Neukam FW and Nkenke E: Early findings of a novel established molecular diagnostic technique for the prediction of malignant transformation in leukoplakia. Mol Med Report 2: 947-952, 2009.
17. Schaaij-Visser TB, Bremmer JF, Braakhuis BJ, Heck AJ, Slijper M, van der Waal I and Brakenhoff RH: Evaluation of cornulin, keratin 4, keratin 13 expression and grade of dysplasia for predicting malignant progression of oral leukoplakia. Oral Oncol 46: 123-127, 2010.
18. Shin DM, Ro JY, Hong WK and Hittelman WN: Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54: 3153-3159, 1994.
19. Smith J, Rattay T, McConkey C, Helliwell T and Mehanna H: Biomarkers in dysplasia of the oral cavity: a systematic review. Oral Oncol 45: 647-653, 2009.
20. Vairaktaris E, Serefoglou Z, Avgoustidis D, Yapijakis C, Critselis E, Vylliotis A, Spyridonidou S, et al: Gene polymorphisms related to angiogenesis, inflammation and thrombosis that influence risk for oral cancer. Oral Oncol 45: 247-253, 2009.
21. Vairaktaris E, Yapijakis C, Derka S, Vassiliou S, Serefoglou Z, Vylliotis A, Wiltfang J, et al: Association of platelet glycoprotein Ia polymorphism with minor increase of risk for oral cancer. Eur J Surg Oncol 32: 455-457, 2006.
22. Yapijakis C, Vairaktaris E, Vassiliou S, Vylliotis A, Nkenke E, Nixon AM, Derka S, et al: The low VEGF production allele of the +936C/T polymorphism is strongly associated with increased risk for oral cancer. J Cancer Res Clin Oncol 133: 787-791, 2007.
23. Oliveira LR and Ribeiro-Silva A: Prognostic significance of immunohistochemical biomarkers in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 40: 298-307, 2011.
24. Ribeiro DC, Gleber-Netto FO, Sousa SF, Bernardes VD, Guimaraes-Abreu MH and Aguiar MC: Immunohistochemical expression of EGFR in oral leukoplakia: association with clinicopathological features and cellular proliferation. Med Oral Patol Oral Cir Bucal 17: e739-744, 2012.
25. Nagatsuka H, Ishiwari Y, Tsujigiwa H, Nakano K and Nagai N: Quantitation of epidermal growth factor receptor gene amplification by competitive polymerase chain reaction in pre-malignant and malignant oral epithelial lesions. Oral Oncol 37: 599-604, 2001.
26. Taoudi Benchekroun M, Saintigny P, Thomas SM, et al: Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res 3: 800-809, 2010.
27. Srinivasan M and Jewell SD: Evaluation of TGF-alpha and EGFR expression in oral leukoplakia and oral submucous fibrosis by quantitative immunohistochemistry. Oncology 61: 284-292, 2001.
28. Srinivasan M and Jewell SD: Quantitative estimation of PCNA, c-myc, EGFR and TGF-α in oral submucous fibrosis - an immunohistochemical study. Oral Oncol 37: 461-467, 2001.
29. Fluss R, Faraggi D and Reiser B: Estimation of the Youden Index and its associated cutoff point. Biom J 47: 458-472, 2005.
30. Brennan M, Migliorati CA, Lockhart PB, Wray D, Al-Hashimi I, Axell T, Bruce AJ, et al: Management of oral epithelial dysplasia: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103 (Suppl 19): S19.e1-S19.e12, 2007.
31. Fleskens SA, Bergshoeff VE, Voogd AC, van Velthuysen ML, Bot FJ, Speel EJ, Kremer B, et al: Interobserver variability of laryngeal mucosal premalignant lesions: a histopathological evaluation. Mod Pathol 24: 892-898, 2011.
32. Holmstrup P, Vedtofte P, Reibel J and Stoltze K: Oral premalignant lesions: is a biopsy reliable? J Oral Pathol Med 36: 262-266, 2007.
33. Napier SS and Speight PM: Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J Oral Pathol Med 37: 1-10, 2008.
34. Angiero F, Berenzi A, Benetti A, Rossi E, Del Sordo R, Sidoni A, Stefani M and Dessy E: Expression of p16, p53 and Ki-67 proteins in the progression of epithelial dysplasia of the oral cavity. Anticancer Res 28: 2535-2539, 2008.
35. Cruz IB, Snijders PJ, Meijer CJ, Braakhuis BJ, Snow GB, Walboomers JM and van der Waal I: p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma. J Pathol 184: 360-368, 1998.
36. Feng CJ, Li HJ, Li JN, Lu YJ and Liao GQ: Expression of Mcm7 and Cdc6 in oral squamous cell carcinoma and precancerous lesions. Anticancer Res 28: 3763-3769, 2008.
37. Grandis JR and Tweardy DJ: TGF-alpha and EGFR in head and neck cancer. J Cell Biochem (Suppl 17): 188-191, 1993.
38. Rautava J, Jee KJ, Miettinen PJ, Nagy B, Myllykangas S, Odell EW, Soukka T, et al: ERBB receptors in developing, dysplastic and malignant oral epithelia. Oral Oncol 44: 227-235, 2008.